Skip NavigationSkip to Content

Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia

  1. Author:
    Wang, Youjin
    Wang, Tao
    Dagnall, Casey
    Haagenson, Michael
    Spellman, Stephen R
    Hicks, Belynda
    Jones, Kristine
    Lee, Stephanie J
    Savage, Sharon A
    Gadalla, Shahinaz M
  2. Author Address

    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA., Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA., Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA., Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Electronic address: gadallas@mail.nih.gov.,
    1. Year: 2017
    2. Date: Jul
    3. Epub Date: 2017 Apr 04
  1. Journal: Biology of Blood and Marrow Transplantation : journal of the American Society for Blood and Marrow Transplantation
    1. 23
    2. 7
    3. Pages: 1054-1058
  2. Type of Article: Article
  1. Abstract:

    Telomeres are tandem nucleotide repeats and a protein complex located at the end of the chromosomes maintaining genomic stability. Their potential as a predictive biomarker for outcomes after allogeneic hematopoietic cell transplant (HCT) in hematologic malignancies is still unclear. From the Center for International Blood and Marrow Transplant Research (CIBMTR), we randomly selected 536 acute leukemia (AL) patients from those who underwent myeloablative 8/8 HLA-matched unrelated donor HCT between 2005 and 2012, and who had an available pre-HCT blood sample in the repository. RTL was measured by real time qPCR. We used Kaplan-Meier and competing risk estimators to calculate survival probability and cumulative incidence, respectively across patient RTL tertiles. Cox proportional hazard regression was used for adjusted analyses. The study included 396 AML and 140 ALL patients. Median age at HCT=41 years, range 0.5-66 years, and median follow-up for survivors=5.1 years (range= 0.4-8.3). Significant inverse correlations between age and RTL were observed in patients with AML (r=-0.44, p< 0.0001), and ALL (r=-0.48 p< 0.0001). Patients with ALL had longer RTL than those with AML (mean T/S= 0.48 vs. 0.43, respectively); the difference was not statistically significant after adjusting for patient age (p=0.96). Pre-HCT RTL in AL patients was not statistically significantly associated with overall survival (HR for longest RTL compared with shortest=0.91, 95% CI=0.65-1.28), disease free survival (HR=0.90, 95% CI=0.64-1.25), transplant related mortality (HR=0.97, 95% CI=0.60-1.59), incidence of relapse (HR=0.89, 95% CI=0.56-1.40), neutrophil engraftment (HR=1.06, 95% CI=0.85-1.32), or acute (HR=1.11, 95% CI=0.81-1.53 for grade II-IV, HR=0.92, 95% CI=0.54-1.59 for grade III-IV) and chronic graft-versus-host disease (HR=1.10, 95% CI=0.81-1.50). In this study, recipient pre-HCT RTL had no prognostic role in post-transplant outcomes in AL patients. Copyright © 2017. Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.bbmt.2017.03.032
  2. PMID: 28389255
  3. WOS: 000404065400004

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel